{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T02:03:41Z","timestamp":1769479421036,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y2019-AZZD-0471"],"award-info":[{"award-number":["Y2019-AZZD-0471"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04331-z","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:34:20Z","timestamp":1766525660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of a hepatocellular carcinoma prognostic model based on the long non-coding RNA RHPN1-AS1"],"prefix":"10.1007","volume":"17","author":[{"given":"Xiaoxuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinchi","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanyu","family":"Leng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wensheng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"3","key":"4331_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4331_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598\u2013606.","journal-title":"J Hepatol"},{"issue":"2","key":"4331_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):169\u201378.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4331_CR4","doi-asserted-by":"publisher","first-page":"1005658","DOI":"10.3389\/fgene.2022.1005658","volume":"13","author":"M Hu","year":"2022","unstructured":"Hu M, Yao W, Shen Q. Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer. Front Genet. 2022;13:1005658.","journal-title":"Front Genet"},{"issue":"7","key":"4331_CR5","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/hep4.1923","volume":"6","author":"RF Reveron-Thornton","year":"2022","unstructured":"Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, et al. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun. 2022;6(7):1813\u201326.","journal-title":"Hepatol Commun"},{"issue":"1","key":"4331_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cell.2013.06.020","volume":"154","author":"I Ulitsky","year":"2013","unstructured":"Ulitsky I, Bartel DP. LincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26\u201346.","journal-title":"Cell"},{"issue":"1","key":"4331_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-020-01188-4","volume":"19","author":"Z Huang","year":"2020","unstructured":"Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020;19(1):77.","journal-title":"Mol Cancer"},{"key":"4331_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.canlet.2017.03.040","volume":"407","author":"ME Forrest","year":"2017","unstructured":"Forrest ME, Khalil AM. Review: regulation of the cancer epigenome by long non-coding RNAs. Cancer Lett. 2017;407:106\u201312.","journal-title":"Cancer Lett"},{"issue":"3","key":"4331_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2174\/0115665232301878240627051455","volume":"25","author":"J Qian","year":"2025","unstructured":"Qian J, Jiang B, Qin Z, Tan Y. Knockdown of hsa_circ_0102231 impedes the progression of liver cancer through the miR-873-SOX4 axis. Curr Gene Ther. 2025;25(3):317\u201326.","journal-title":"Curr Gene Ther"},{"issue":"16","key":"4331_CR10","doi-asserted-by":"publisher","first-page":"e2207074","DOI":"10.1002\/advs.202207074","volume":"10","author":"C Xue","year":"2023","unstructured":"Xue C, Gu X, Zheng Q, Shi Q, Yuan X, Chu Q, Jia J, Su Y, Bao Z, Lu J, et al. Effects of 3-HAA on HCC by regulating the heterogeneous Macrophages-A scRNA-Seq analysis. Adv Sci (Weinh). 2023;10(16):e2207074.","journal-title":"Adv Sci (Weinh)"},{"key":"4331_CR11","doi-asserted-by":"crossref","unstructured":"Lu L, Yu X, Zhang L, Ding X, Pan H, Wen X, Xu S, Xing Y, Fan J, Ge S et al. The long Non-Coding RNA RHPN1-AS1 promotes uveal melanoma progression. Int J Mol Sci 2017, 18(1).","DOI":"10.3390\/ijms18010226"},{"issue":"17","key":"4331_CR12","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.7150\/jca.29029","volume":"10","author":"X Qiu","year":"2019","unstructured":"Qiu X, Lei Z, Wang Z, Xu Y, Liu C, Li P, Wu H, Gong Z. Knockdown of LncRNA RHPN1-AS1 inhibits cell Migration, invasion and proliferation in head and neck squamous cell carcinoma. J Cancer. 2019;10(17):4000\u20138.","journal-title":"J Cancer"},{"issue":"6","key":"4331_CR13","first-page":"3505","volume":"11","author":"S Zheng","year":"2019","unstructured":"Zheng S, Lv P, Su J, Miao K, Xu H, Li M. Silencing of the long non-coding RNA RHPN1-AS1 suppresses the epithelial-to-mesenchymal transition and inhibits breast cancer progression. Am J Transl Res. 2019;11(6):3505\u201317.","journal-title":"Am J Transl Res"},{"key":"4331_CR14","doi-asserted-by":"publisher","first-page":"109848","DOI":"10.1016\/j.biopha.2020.109848","volume":"124","author":"L Ding","year":"2020","unstructured":"Ding L, Wang L, Li Z, Jiang X, Xu Y, Han N. The positive feedback loop of RHPN1-AS1\/miR-1299\/ETS1 accelerates the deterioration of gastric cancer. Biomed Pharmacother. 2020;124:109848.","journal-title":"Biomed Pharmacother"},{"issue":"43","key":"4331_CR15","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.2174\/1381612825666191105104549","volume":"25","author":"H Fen","year":"2020","unstructured":"Fen H, Hongmin Z, Wei W, Chao Y, Yang Y, Bei L, Zhihua S. RHPN1-AS1 drives the progression of hepatocellular carcinoma via regulating miR-596\/IGF2BP2 axis. Curr Pharm Des. 2020;25(43):4630\u201340.","journal-title":"Curr Pharm Des"},{"key":"4331_CR16","doi-asserted-by":"publisher","first-page":"3502981","DOI":"10.1155\/2020\/3502981","volume":"2020","author":"ZN Li","year":"2020","unstructured":"Li ZN, Ge MX, Cao LJ, Yuan ZF. LncRNA RHPN1-AS1 serves as a sponge for miR-3133 modulating the cell proliferation of retinoblastoma through JAK2. Biomed Res Int. 2020;2020:3502981.","journal-title":"Biomed Res Int"},{"issue":"5","key":"4331_CR17","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.18632\/aging.102911","volume":"12","author":"J Wang","year":"2020","unstructured":"Wang J, Ding W, Xu Y, Tao E, Mo M, Xu W, Cai X, Chen X, Yuan J, Wu X. Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a CeRNA against miR-596 and upregulating LETM1. Aging. 2020;12(5):4558\u201372.","journal-title":"Aging"},{"issue":"3","key":"4331_CR18","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.3892\/ol.2020.11773","volume":"20","author":"Y Wu","year":"2020","unstructured":"Wu Y, Wei W, Tang L, Wang L. Prognostic potential of LncRNA RHPN1-AS1 in glioma. Oncol Lett. 2020;20(3):2442\u20136.","journal-title":"Oncol Lett"},{"key":"4331_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12935-020-1110-9","volume":"20","author":"W Zheng","year":"2020","unstructured":"Zheng W, Li H, Zhang H, Zhang C, Zhu Z, Liang H, Zhou Y. Long noncoding RNA RHPN1-AS1 promotes colorectal cancer progression via targeting miR-7-5p\/OGT axis. Cancer Cell Int. 2020;20:54.","journal-title":"Cancer Cell Int"},{"issue":"1\u20132","key":"4331_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41417-020-0180-0","volume":"28","author":"J Zhao","year":"2021","unstructured":"Zhao J, Yang T, Ji J, Zhao F, Li C, Han X. RHPN1-AS1 promotes cell proliferation and migration via miR-665\/Akt3 in ovarian cancer. Cancer Gene Ther. 2021;28(1\u20132):33\u201341.","journal-title":"Cancer Gene Ther"},{"key":"4331_CR21","doi-asserted-by":"publisher","first-page":"104671","DOI":"10.1016\/j.yexmp.2021.104671","volume":"122","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Zhou H, Dong W. LncRNA RHPN1-AS1 promotes the progression of nasopharyngeal carcinoma by targeting CELF2 expression. Exp Mol Pathol. 2021;122:104671.","journal-title":"Exp Mol Pathol"},{"issue":"12","key":"4331_CR22","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1002\/tox.23656","volume":"37","author":"X Ma","year":"2022","unstructured":"Ma X, Ren H, Zhang Y, Wang B, Ma H. LncRNA RHPN1-AS1 Inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p\/EGFR\/PI3K\/AKT\/mTOR signaling pathway. Environ Toxicol. 2022;37(12):3013\u201327.","journal-title":"Environ Toxicol"},{"key":"4331_CR23","doi-asserted-by":"publisher","first-page":"116856","DOI":"10.1016\/j.lfs.2019.116856","volume":"239","author":"H Duan","year":"2019","unstructured":"Duan H, Li X, Chen Y, Wang Y, Li Z. LncRNA RHPN1-AS1 promoted cell proliferation, invasion and migration in cervical cancer via the modulation of miR-299-3p\/FGF2 axis. Life Sci. 2019;239:116856.","journal-title":"Life Sci"},{"key":"4331_CR24","doi-asserted-by":"crossref","unstructured":"Zhang X, Yan Z, Wang L, Zhang S, Gao M. STAT1-induced upregulation of LncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485\/CDCA5 axis. J Cell Biochem 2020.","DOI":"10.1002\/jcb.29689"},{"key":"4331_CR25","doi-asserted-by":"crossref","unstructured":"Cui S, Li F. RHPN1\u2013AS1 promotes ovarian carcinogenesis by sponging miR\u20136884\u20135p thus releasing TOP2A mRNA. Oncol Rep 2021, 46(4).","DOI":"10.3892\/or.2021.8172"},{"issue":"2","key":"4331_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","volume":"173","author":"J Liu","year":"2018","unstructured":"Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, et al. An integrated TCGA Pan-Cancer clinical data resource to drive High-Quality survival outcome analytics. Cell. 2018;173(2):400\u2013e416411.","journal-title":"Cell"},{"issue":"9","key":"4331_CR27","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468.","journal-title":"PLoS ONE"},{"issue":"1","key":"4331_CR28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.7150\/ijbs.50730","volume":"17","author":"D Yuan","year":"2021","unstructured":"Yuan D, Chen Y, Li X, Li J, Zhao Y, Shen J, Du F, Kaboli PJ, Li M, Wu X, et al. Long Non-Coding rnas: potential biomarkers and targets for hepatocellular carcinoma therapy and diagnosis. Int J Biol Sci. 2021;17(1):220\u201335.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"4331_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/0113892029273682240111052317","volume":"25","author":"R Mu","year":"2024","unstructured":"Mu R, Chang M, Feng C, Cui Y, Li T, Liu C, Wang Y, Guo X. Analysis of the expression of PRDX6 in patients with hepatocellular carcinoma and its effect on the phenotype of hepatocellular carcinoma cells. Curr Genomics. 2024;25(1):2\u201311.","journal-title":"Curr Genomics"},{"issue":"3","key":"4331_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/carcin\/bgt351","volume":"35","author":"SF Mahmood","year":"2014","unstructured":"Mahmood SF, Gruel N, Chapeaublanc E, Lescure A, Jones T, Reyal F, Vincent-Salomon A, Raynal V, Pierron G, Perez F, et al. A SiRNA screen identifies RAD21, EIF3H, CHRAC1 and TANC2 as driver genes within the 8q23, 8q24.3 and 17q23 amplicons in breast cancer with effects on cell growth, survival and transformation. Carcinogenesis. 2014;35(3):670\u201382.","journal-title":"Carcinogenesis"},{"issue":"2","key":"4331_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1245\/s10434-015-5031-0","volume":"24","author":"R Desaki","year":"2017","unstructured":"Desaki R, Sawada G, Okumura H, Ikeda R, Tanabe K, Komatsu H, Mimori K, Mori M, Kita Y, Uchikado Y, et al. As a novel prognostic Marker, Cysteine\/histidine-rich 1 (CYHR1) is a therapeutic target in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2017;24(2):586\u201393.","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"4331_CR32","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1038\/onc.2015.347","volume":"35","author":"L Pangon","year":"2016","unstructured":"Pangon L, Ng I, Giry-Laterriere M, Currey N, Morgan A, Benthani F, Tran PN, Al-Sohaily S, Segelov E, Parker BL, et al. JRK is a positive regulator of \u03b2-catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer. Oncogene. 2016;35(22):2834\u201341.","journal-title":"Oncogene"},{"issue":"1","key":"4331_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.20892\/j.issn.2095-3941.2020.0105","volume":"18","author":"G Lyu","year":"2021","unstructured":"Lyu G, Su P, Hao X, Chen S, Ren S, Zhao Z, Gong Y, Liu Q, Shao C. RECQL4 regulates DNA damage response and redox homeostasis in esophageal cancer. Cancer Biol Med. 2021;18(1):120\u201338.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"4331_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12943-021-01451-2","volume":"20","author":"B Chen","year":"2021","unstructured":"Chen B, Chan WN, Mui CW, Liu X, Zhang J, Wang Y, Cheung AHK, Chan AKY, Chan RCK, Leung KT, et al. STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker. Mol Cancer. 2021;20(1):147.","journal-title":"Mol Cancer"},{"issue":"5","key":"4331_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.prp.2019.01.044","volume":"215","author":"B Yu","year":"2019","unstructured":"Yu B, Ding Y, Liao X, Wang C, Wang B, Chen X. Overexpression of TONSL might be an independent unfavorable prognostic indicator in hepatocellular carcinoma. Pathol Res Pract. 2019;215(5):939\u201345.","journal-title":"Pathol Res Pract"},{"key":"4331_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.08.024","volume":"437","author":"Y Huang","year":"2018","unstructured":"Huang Y, Xiang B, Liu Y, Wang Y, Kan H. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p\/NAP1L1 axis. Cancer Lett. 2018;437:56\u201366.","journal-title":"Cancer Lett"},{"issue":"12","key":"4331_CR37","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1007\/s00210-020-01889-z","volume":"393","author":"W Zhang","year":"2020","unstructured":"Zhang W, Han L, Xing P, Liu B, Sun Z, Zhou W, Dong J. LncRNA RHPN1-AS1 accelerates proliferation, migration, and invasion via regulating miR-485-5p\/BSG axis in hepatocellular carcinoma. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(12):2543\u201351.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"4331_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/0115665232274223231017052707","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, Sun L, Liu Y, Zhang Y. FIGNL1 promotes hepatocellular carcinoma formation via remodeling ECM-receptor interaction pathway mediated by HMMR. Curr Gene Ther. 2024;24(3):249\u201363.","journal-title":"Curr Gene Ther"},{"issue":"40","key":"4331_CR39","doi-asserted-by":"publisher","first-page":"e21503","DOI":"10.1097\/MD.0000000000021503","volume":"99","author":"Z Bai","year":"2020","unstructured":"Bai Z, Li H, Li C, Sheng C, Zhao X. Integrated analysis identifies a long non-coding RNAs-messenger RNAs signature for prediction of prognosis in hepatitis B virus-hepatocellular carcinoma patients. Medicine. 2020;99(40):e21503.","journal-title":"Medicine"},{"key":"4331_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12935-019-0771-8","volume":"19","author":"XT Fu","year":"2019","unstructured":"Fu XT, Song K, Zhou J, Shi YH, Liu WR, Shi GM, Gao Q, Wang XY, Ding ZB, Fan J. Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. Cancer Cell Int. 2019;19:71.","journal-title":"Cancer Cell Int"},{"issue":"13","key":"4331_CR41","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","volume":"23","author":"D Tripathy","year":"2017","unstructured":"Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective Cyclin-Dependent kinase 4\/6 inhibitor in various solid tumors. Clin Cancer Res. 2017;23(13):3251\u201362.","journal-title":"Clin Cancer Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04331-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04331-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04331-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:25:52Z","timestamp":1769441152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04331-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4331"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04331-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TCGA specimens were obtained with written informed consent under an Institutional Review Board (IRB) approved protocol in accordance with recognized ethical guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"155"}}